Recently, the biomarkers that are most extensively utilized in clinical practice are PD-L1 expression, which is evaluated through immunohistochemistry (IHC), and tumor mutation burden (TMB), which is determined through next-generation sequencing (NGS) technology (1). Here, CD274 is linked to neoplasm.